Diligence memo · auto-generated · as of July 2, 2026

Resolute Science, Inc.

Resolute Science, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 5.4× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Resolute Science, Inc. operates in Biotechnology, based in San Diego.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Resolute Science, Inc. has raised $1.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.4M on 2025-02-03.

Most recent recorded round closed around 2025-02-03.

Valuation (modeled)modeled

Provath models Resolute Science, Inc. at approximately $4.7M (range $972K–$11M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.03× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 17 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 5.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 25% of Biotechnology peers (4293 compared).

Modeled value ranks above 10% of those peers.

Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.